Sc 44236

Manufactured by Santa Cruz Biotechnology

Sourced in United States

Sc-44236 is a laboratory equipment product offered by Santa Cruz Biotechnology. It serves as a core function for various experimental applications.

Automatically generated - may contain errors

Lab products found in correlation

Sc 37007, by Santa Cruz Biotechnology (2 mentions) Lipofectamine 2000 reagent, by Thermo Fisher Scientific (2 mentions) Notch2 sirna, by Santa Cruz Biotechnology (1 mentions) Lipofectamine 2000, by Thermo Fisher Scientific (1 mentions) Rnaifectin transfection reagent, by Applied Biological Materials (1 mentions) D 001810 01, by Horizon Discovery (1 mentions) D 001810 02, by Horizon Discovery (1 mentions) Sc 38637, by Santa Cruz Biotechnology (1 mentions) Human chondrocyte nucleofector solution, by Lonza (1 mentions) Amaxa nucleofector 2, by Lonza (1 mentions)

4 protocols using sc 44236

Notch2 Knockdown and GC Cell Viability

Check if the same lab product or an alternative is used in the 5 most similar protocols

Notch2-siRNA (sc-40135, Santa Cruz Biotechnology, Inc) is the target-specific 19-25 nt siRNA designed to knock down human Notch2 gene expression. For siRNA transfection, GC cells were seeded into 6-well plates to be grown to sub-confluency and transiently transfected with negative control siRNA (sc-44236, Santa Cruz Biotechnology, Inc) or Notch2-siRNA at 50 nM for 24 h using Lipofectamine 2000 (Invitrogen, San Diego, CA, USA) according to the manufacturer’s instruction. The next day, the medium was changed to fresh medium with or without ACGs (5 μg/ml), and the cells were continually cultured for 24 h. The proteins were extracted from cells to measure Notch2 expression by western blot and the cell viability was detected by MTS assay.

Li Y., Ye J., Chen Z., Wen J., Li F., Su P., Lin Y., Hu B., Wu D., Ning L., Xue Q., Gu H, & Ning Y. (2017). Annonaceous acetogenins mediated up-regulation of Notch2 exerts growth inhibition in human gastric cancer cells in vitro. Oncotarget, 8(13), 21140-21152.

+ Open protocol

+ Expand

Knockdown of DLL3 Gene in Gastric Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

siRNA–DLL3s were the target-specific 19- to 25-nt siRNAs designed to knock down the human DLL3 gene. For siRNA transfection, MKN45 and BCG823 cells were seeded into six-well plates to grow to subconfluency and transiently transfected with negative control siRNA (sc-37007; Santa Cruz Biotechnology, Inc.; Santa Cruz, CA, USA) or siRNA–DLL3 (sc-44236; Santa Cruz Biotechnology, Inc.) at 50 nM for 24 h using RNAifectin Transfection Reagent (G073; Applied Biological Materials; Richmond, British Columbia, Canada).

Ye J.B., Wen J.J., Wu D.L., Hu B.X., Luo M.Q., Lin Y.Q., Ning Y.S, & Li Y. (2021). Elevated DLL3 in stomach cancer by tumor-associated macrophages enhances cancer-cell proliferation and cytokine secretion of macrophages. Gastroenterology Report, 10, goab052.

+ Open protocol

+ Expand

Modulating Cell Signaling Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

Pre-miRNA oligonucleotides (pre-miR-130a, negative control pre-miR-NC1, and premiR-NC2) and custom-designed tiny LNA oligonucleotides (tiny-130: 5′-ATTGCACT-3′ and tiny-NC: 5′-TCATACTA-3′) were purchased from Thermo Scientific/Ambion and Exiqon, respectively. siR-NAs for PPARγ (sc-29455), OCT4/POU5F1 (sc-5279), and scrambled control (sc-44236) were purchased from Santa Cruz Biotechnology. On Target Plus siRNAs for YAP (J-012200-07), TAZ (WWTR1) (J-016083-05), LRP8 (J-011802-05), and scrambled control (D-001810-01) were purchased from Dharmacon (GE Healthcare). PAAFs, PAECs, and PASMCs were plated in collagen-coated plastic (50ug/mL) and transfected 24h later at 70–80% confluence using pre-miRNA (5nM), tiny-LNA (20nM), or siRNA (25nM) and Lipofectamine 2000 reagent (Thermo Scientific), according to the manufacturers’ instructions. Eight hours after transfection, cells were trypsinized and re-plated in hydrogel. Key siRNA experiments were replicated with two independent siRNA sequences targeting YAP (J-012200-05, Dharmacon), TAZ (J-016083-06, Dharmacon), PPARγ (sc-44220, Santa Cruz Biotechnology), and LRP8 (J-011802-06, Dharmacon) as well as scrambled controls (sc-37007 Santa Cruz Biotechnology and D-001810-02 Dharmacon).

Bertero T., Cottrill K.A., Lu Y., Haeger C.M., Dieffenbach P., Annis S., Hale A., Bhat B., Kaimal V., Zhang Y.Y., Graham B.B., Kumar R., Saggar R., Saggar R., Wallace W.D., Ross D.J., Black S.M., Fratz S., Fineman J.R., Vargas S.O., Haley K.J., Waxman A.B., Chau B.N., Fredenburgh L.E, & Chan S.Y. (2015). Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP/TAZ-miR-130/301 circuit. Cell reports, 13(5), 1016-1032.

+ Open protocol

+ Expand

Knockdown of YAP and MRTF-A in Primary Human NP Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

siRNA pools of gene-specific 19–25 nt sequences targeting YAP and MRTF-A designed to knock down mRNA were purchased from Santa Cruz Biotechnology (sc-38637 and sc-43944, respectively) along with a nontargeting 20–25-nt siRNA designed as a negative scramble control (sc-44236). Primary human NP cells, cultured no longer than passage 1, were tryspinized, counted, and centrifuged at 0.5 × 10⁶ cells per siRNA construct. Nucleofection was used to deliver the siRNA using the Amaxa Nucleofector II (Lonza, Basel, Switzerland) using a modified protocol from the manufacturer for primary human chondrocytes. Cells were resuspended in 100 ml of room-temperature Human Chondrocyte Nucleofector Solution (Lonza). Five micrograms of DNA was added and immediately transferred to a cuvette for nucleofection (program T-030). Following nucleofection, 500 ml of prewarmed 20% FBS containing F-12 medium was added and gently transferred to a prewarmed 6-well plate. Following 24 h incubation, medium was replaced with 10% FBS F-12 medium. All siRNA experiments were conducted 48 h postnucleofection.

Fearing B.V., Jing L., Barcellona M.N., Witte S.E., Buchowski J.M., Zebala L.P., Kelly M.P., Luhmann S., Gupta M.C., Pathak A, & Setton L.A. (2019). Mechanosensitive transcriptional coactivators MRTF-A and YAP/TAZ regulate nucleus pulposus cell phenotype through cell shape. The FASEB Journal, 33(12), 14022-14035.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!